Current Affairs - June, 2020

This category comprises latest Current Affairs of June, 2020 with news summary on current events of National and International importance. Current Affairs June, 2020 for Banking, SSC, CLAT, UPSC, State PCS, IBPS, Railways and other Competitive Examinations.

PDF Compilation of these updates can be downloaded from This Link

U.S. Temporarily Suspends ‘Green Cards & Non-Migrant Work Visas’ till 31st December 2020

Following a global economic crisis since the COVID-19 was declared a pandemic back in March 2020, the United States Government has decided to suspend ‘Green Cards and Non-Migrant Work Visas’ till the 31st December 2020 in an effort to protect jobs for the citizens of the United States.

The executive order was signed by the United States President Donald Trump on 22nd June 2020.


The suspension of Green Card and Non-migrant work visas will create around 5,25,000 jobs in the United States. Due to COVID-19, as per reports, a record 47 million could lose their jobs in the United States.

Suspended Work Visas

  1. H-1B
  2. H-4 for some H-1B spouses
  3. H-2B for low skill workers
  4. L-1 for Intra-Company Transfers
  5. J Visas for Educational and Cultural Workers

Reform in H-1B Visa Programme

President Donald Trump had also instructed his administration to make reform in the current H-1B Visa Programme.  As per the reform, immigrant workers those who are offered the highest wages by the recruiter shall be given priority, this is to ensure that the wages of United States citizens are protected as employers will not be able to recruit low-cost foreign labour.

Until today, the H-1B visas were distributed through a random lottery.

Impact on India

Every year H-1B Visas are issued to 85,000 only, out of these, as per the records the largest beneficiaries of the visa programme was the Indians. A more than 70 percent of the total 85,000 beneficiaries are from India.

Cipla’s ‘Cipremi’ gets approval for Treatment of COVID-19 Patients in India

In its June 13th, 2020 guidelines for Clinical Management Protocol for COVID-19, the Union Health Ministry as a part of investigational therapy added ‘Remdesivir’ only for restricted emergency use. A week after, on 21st June 2020, Hetero and Cipla Pharmaceuticals were granted approval by the Drug Controller General of India for the production and marketing of the antiviral drug under its respective generic names.

The United States-based biopharmaceutical company, Gilead Sciences is the developer of the drug. In May 2020 Cipla was granted the voluntary non-exclusive by Gilead Science for manufacturing and marketing of the drug in India under generic drug name ‘CIPREMI’.

Japan was the first country to approve Remdesivir drug as a treatment for COVID-19. At present Remdesivir is only available in the injectable method. On 22nd June 2020, Gilead Sciences had announced had it will soon start Phase I trial for the inhaled version of Remdesivir.


In May 2020, clinical trials conducted under ACTT-1 (Adaptive COVID-19 Treatment Trial) with Remdesivir in more than 60 centers across the United States, Asia, and Europe had shown promising results when compared with the patients who were given placebo. During the trails a total of 1063 patients were given Remdesivir, the mortality rate was 7.1 %.